Navigation Links
Reportlinker Adds The Cancer Market Outlook to 2016
Date:6/20/2011

NEW YORK, June 20, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Cancer Market Outlook to 2016

http://www.reportlinker.com/p0558644/The-Cancer-Market-Outlook-to-2016.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Introduction

The global cancer market is becoming increasingly competitive, with two therapeutic classes, namely antineoplastics and cytostatic hormonal treatments, dominating this sector. This report presents leading products, developments, and market forecasts for each of these classes. Eighteen recently launched/late-stage pipeline products are discussed in detail.

Features and benefits

* Understand how recent events are affecting the performance of major products, and how companies are confronting competitive market changes.

* Compare the franchises of the leading companies in the cancer market, and understand how the market share of these companies will change.

* Assess key pipeline products by indication, ongoing trials, recent product launches, and key developments in R&D.

* Identify the challenges faced by leading players, and understand how recent events will impact the performance of leading products.

* Gain insights into the forecasts of the leading marketed and pipeline products through to 2016.

Highlights

The key factor for growth of the cancer therapy market is the expansion of target indications. Most of the blockbuster drugs were launched for a narrow indication, but later gained approval for a wider range of indications.

Regardless of indication, the key challenge in ensuring the commercial success of pipeline drugs is to ascertain their integration into current treatment regimens either in combination with existing therapies or by demonstrating significant superiority over current treatments.

Pricing risk remains the key investment concern in cancer. Moreover, the level of scrutiny by payers regarding the cost-effectiveness of cancer treatments has intensified in recent years.

Your key questions answered

* What will be the major growth indications and the accompanying growth drivers in the cancer market over the next 6 years?

* Which were the leading players in the cancer market in 2010?

* Which products will be the future growth drivers for the cancer health market?

* Which therapeutic categories are forecast to have the highest levels of commercial potential over the period 2010–16?

* Which companies are best positioned to succeed in the cancer market over the period 2010–16?

Executive Summary

Overview and epidemiology of women's health

Global market analysis

Pipeline analysis

Competitive landscape

About the author

Disclaimer

Overview and epidemiology of women's health

Summary

Introduction

Osteoporosis

Overview

Diagnosis treatment and management

Epidemiology

Forecast epidemiology

Hormonal contraception

Overview

Diagnosis treatment and management

Epidemiology

Forecast epidemiology

Hormone replacement therapies

Overview

Diagnosis, treatment and management

Infertility treatment

Overview

Diagnosis, treatment and management

Epidemiology

Forecast epidemiology

Global market analysis

Summary

Market analysis by geography

Market analysis by therapy area

Hormonal contraceptives

Osteoporosis treatment

Hormone replacement therapy (HRT)

Infertility treatment

Key events in women's health market

Merck Serono sells women's health division to Teva

Gedeon Richter extends women's health franchise with PregLem acquisition

Boehringer Ingelheim discontinued the development of its female desire drug, flibanserin

Eli Lilly's arzoxifene misses secondary endpoint in critical osteoporosis trial

Bayer's Yaz and Yasmin get US label update

Research deal between Bayer and Chinese hospital for women's health

Leading brand dynamics

Actonel (Risedronate) – Warner Chilcott, Sanofi

Evista (raloxifene) – Eli Lilly

Bonviva/Boniva (ibandronic acid) – Roche/GlaxoSmithKline

Premarin (conjugated estrogens) – Pfizer

Fosamax (alendronate) – Merck & Co

Yaz/Yasmin (drospirenone + ethinyl estradiol) – Bayer

Mirena (levonorgestrel) – Bayer

Gonal F (follitropin beta) – Merck KGaA

NuvaRing (ethinyl estradiol + etonogestrel) – Merck & Co.

Global women's health sales forecast

Pipeline analysis

Summary

Introduction

Women's health pipeline

Leading drugs in development

Profiles of key pipeline products

Prolia (denosumab) – Amgen

Viviant/Conbriza (bazedoxifene) – Pfizer

LCS (ultra low-dose levonorgestrel releasing IUD) – Bayer

Aprela (bazedoxifene and conjugated estrogen) – Pfizer

MK-0822 (odanacatib) – Merck

Elonva (corifollitropin alfa) – Merck

Nomac E2 (nomegestrol and estradiol) – Merck & Co.

WC3026/ Generess (norethindrone + ethinyl estradiol) – Warner Chilcott/Watson

Natazia/Qlaira (estradiol valerate and dienogest) – Bayer

SMC021 (synthetic oral salmon calcitonin) – Novartis

FC Patch Low (gestodene and ethinyl estradiol transdermal patch) – Bayer

DR2011 (progesterone vaginal ring) – Teva

EllaOne (ulipristal acetate) – HRA Pharma/Watson

Pipeline forecast of leading drugs in development

Competitive landscape

Summary

Introduction

Sales performance of leading players

Bayer

Marketed product portfolio

Pipeline analysis

Strategic and growth analysis

Merck & Co.

Marketed product portfolio

Pipeline analysis

Strategic and growth analysis

Eli Lilly

Marketed product portfolio

Pipeline analysis

Strategic and growth analysis

Warner Chilcott

Marketed product portfolio

Pipeline analysis

Strategic and growth analysis

Pfizer

Marketed product portfolio

Pipeline analysis

Strategic and growth analysis

Teva

Marketed product portfolio

Pipeline analysis

Strategic and growth analysis

Appendix

Scope

Key women's health diseases covered in this report

Methodology

Epidemiology forecast

Market forecast

Epidemiology forecast

References

Journal articles

Conference proceedings

Important websites

Glossary/abbreviations

To order this report:

Pathology Industry: The Cancer Market Outlook to 2016

Pathology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Reportlinker Adds India Biotechnology in India Industry
2. Reportlinker Adds Global Immunochemicals Industry
3. Reportlinker Adds Industrial Biotechnology China News 1105 - Annual Subscription
4. Reportlinker Adds Future of White Biotechnology in China
5. Reportlinker Adds Whats Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015
6. Reportlinker Adds Orthopedic Biomaterials, The World Market
7. Reportlinker Adds Biochips and Microarrays - Technologies, markets and companies
8. Reportlinker Adds Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017
9. Reportlinker Adds Future Directions in Regenerative Medicine
10. Reportlinker Adds Innovations in Protein Kinase Therapies - Significant Proportion of Protein Kinase Pipeline Contains Small Molecule Drugs That Target Oncology
11. Reportlinker Adds Technology Transfer Strategies - A Guide to Maximizing Returns Within the Pharmaceutical and Biopharmaceutical Industries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... DIEGO, Feb. 11, 2016  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ... ended December 31, 2015. --> ... a net loss of $29.3 million, or $0.34 loss per share, ... per share for the same period in 2014. For the year ... $88.9 million, or $1.05 loss per share, as compared to a ...
(Date:2/11/2016)... , Germany and ... QGEN ; Frankfurt Prime Standard: QIA) today ... Targeted RNA Panels for gene expression profiling, expanding QIAGEN,s ... (NGS). The panels enable researchers to select from over ... changes and discover interactions between genes, cellular phenotypes and ...
(Date:2/11/2016)... 2016  Spectra BioPharma Selling Solutions (Spectra) is ... biopharma companies the experience, expertise, operational delivery and ... sales teams. Created in concert with industry leading ... strategic and tactical needs of its clients by ... both personal and non-personal promotion. ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... dedicated to delivering cutting-edge information focused on the development and manufacture of ... become a premier sponsor of the 2016 BioProcess International Awards – Recognizing ...
Breaking Biology Technology:
(Date:1/25/2016)... SEATTLE , Jan. 25, 2016  Glencoe Software, ... biotech, pharma and publication industries, will provide the data ... Phenotypic Screening Centre (NPSC). ... Phenotypic analysis ... even whole organisms, allowing comparisons between states such as ...
(Date:1/20/2016)... Minn. , Jan. 20, 2016   MedNet ... supports the entire spectrum of clinical research, is pleased ... 2015. MedNet,s significant achievements are the result of the ... iMedNet eClinical , it,s comprehensive, easy-to-use ... --> --> Key MedNet growth achievements ...
(Date:1/13/2016)... , January 13, 2016 ... the addition of the  "India Biometrics ... & Forecast (2015-2020)"  report to ... ) has announced the addition of ... Market - Estimation & Forecast (2015-2020)" ...
Breaking Biology News(10 mins):